SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.87-2.3%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (240)6/18/1999 9:22:00 AM
From: Mike K   of 52153
 
Rick;

Thanks for your analysis! I look forward to reading your posts.
PNU looks interesting with the addition of SUGN. Don't know much about them, but I'm starting my DD.

Novartis currently has a large clinical trial going on with Zoledronate (over 1500 patients in Canada). Although this drug will probably replace Aredia (pamidronate), these bisphosphonates have large market potential in Europe and Asia, where oral bisphosponates are much more common.

Cheers,

Mike
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News